Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Chodakewitz Jeffrey      |   |  |   |          |                              | 2. Issuer Name and Ticker or Trading Symbol  VERTEX PHARMACEUTICALS INC /  MA [ VRTX ] |       |   |  |  |                         |   |                                   | 5. Relationship (Check all appl Direct X Office below                    |  | able)   | g Pers | 10% O<br>Other (below)   | wner                                  |  |
|--|---|--|---|----------|------------------------------|--|-------|---|--|--|-------------------------|---|-----------------------------------|--|--|---|--------|--|---------------------------------------|--|
| (Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED    |   |  |   |          |                              | 3. Date of Earliest Transaction (Month/Day/Year) 03/29/2017                            |       |   |  |  |                         |   |                                   |  | EVP GMDA, CMO                                |   |        |  |                                       |  |
| 50 NORTHERN AVENUE   |   |  |   |          |                              | 4. If Amendment, Date of Original Filed (Month/Day/Year)                               |       |   |  |  |                         |   |                                   | 6. Individual or Joint/Group Filing (Check Applicable                    |  |   |        |  |                                       |  |
| (Street) BOSTON MA 02210   |   |  |   |          |                              |  |       |   |  |  |                         |   | Line)<br>X                        | Form filed by One Reporting Person Form filed by More than One Reporting |  |   |        |  |                                       |  |
| (City) (State) (Zip)   |   |  |   | -        |                              |  |       |   |  |  |                         |   |                                   | Person   |  |   |        |  |                                       |  |
| (9)  |   | ·  |   | Non-Deri | ivativ                       | e Sec  | curit | ties Ad                                 | cauire   | ed. D  | isposed o               | of. or B  | enefic                            | ially  | Owned  |   |        |  |                                       |  |
| 1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye |   |  |   | tion     | 2A. D<br>Exec<br>if any      | A. Deemed<br>xecution Date,  |       | 3.<br>Transaction<br>Code (Instr.<br>8) |  | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 an |                         |   |                                   | 5. Amou<br>Securiti<br>Benefic<br>Owned                                  | int of<br>es<br>ially<br>Following           | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)   |        | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership            |                                       |  |
|  |   |  |   |          |                              |  |       | Code                                    | v  | Amount   | (A) or<br>(D)           | Price   |                                   | Reporte<br>Transac<br>(Instr. 3  | ction(s)                                     |   |        | (Instr. 4)   |                                       |  |
| Common Stock 03/29/201   |   |  |   |          | 2017                         | 7  |       |   | M  |  | 13,750                  | A   | \$73                              | \$73.51  |  | 6,261   |        | D  |                                       |  |
| Common Stock 03/29/201   |   |  |   | 2017     | .7                           |  |       | S <sup>(1)</sup>                        |  | 13,750   | D                       | \$106.6   | 106.65 <sup>(2)(3)</sup>          |  | 2,511  |   | D      |  |                                       |  |
|  |   | -  | Table   |          |                              |  |       |   |  |  | posed of,<br>, converti |   |                                   |  | wned   |   |        |  |                                       |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | Execution Date,<br>if any<br>(Month/Day/Year) |          | 4.<br>Transa<br>Code (<br>8) |  |       |   | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |  |                         | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                                   | D  | Price of<br>erivative<br>ecurity<br>nstr. 5) | 9. Number<br>derivative<br>Securities<br>Beneficial<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | illy   | Ownershi<br>Form:<br>Direct (D)<br>or Indirec<br>(I) (Instr. 4 | Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |  |   |          | Code                         | v  | (A)   | (D)                                     | Date<br>Exerc  | isable   | Expiration<br>Date      | Title   | Amor<br>or<br>Numl<br>of<br>Share | ber  |  |   |        |  |                                       |  |
| Stock<br>Option<br>(Right to<br>Buy)                               | \$73.51   | 03/29/2017                                 |   |          | M                            |  |       | 13,750                                  | (4   | 4)   | 01/01/2024              | Commo   | n 13,7                            | 50   | \$0.00                                       | 20,625  | 5      | D  |                                       |  |

## **Explanation of Responses:**

- 1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- 2. Open market sales reported on this line occurred at a weighted average price of \$106.65 (range \$106.30 to \$107.00).
- 3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. The option vests in 16 quarterly installments from 01/02/2014.

## Remarks:

Omar White, Attorney-In-Fact 03/31/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.